Sarah Egert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah Egert has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Helmut F. Erbersdobler
Institute of Human Nutrition and Food Science, University of Kiel, 24105 Kiel, Germany
2 shared publicationsUrsel Wahrburg
Department of Human Nutrition, University of Applied Sciences, 48149 Muenster, Germany
2 shared publications- Veronika Somoza
Leibniz-Institute for Food Systems Biology at the Technical University of Munich, Freising, Germany
2 shared publications - Anne-Christin Graeser
Institute of Human Nutrition and Food Science, Christian Albrechts University of Kiel, Hermann-Rodewald-Strasse 6, Kiel 24098, Germany
1 shared publication - Christine Boesch
University of Leeds
1 shared publication - Frank Doering
Institute of Human Nutrition and Food Science, Christian Albrechts University Kiel, Olshausenstrasse 40, D-24118 Kiel, Germany
1 shared publication
Latest Publications
- Open Access
- 23 September 2009
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 10 (9) , 4168-4177
Effect of Quercetin on Paraoxonase 2 Levels in RAW264.7 Macrophages and in Human Monocytes—Role of Quercetin Metabolism
There is increasing evidence that the intracellular antioxidant enzyme paraoxonase 2 (PON2) may have a protective function in the prevention of atherogenesis. An enhancement of PON2 activity by dietary factors including flavonoids is therefore of interest. In the present study we determined the effect of quercetin on paraoxonase 2 levels in cultured murine macrophages in vitro and in overweight subjects with a high cardiovascular risk phenotype supplemented with 150 mg quercetin/day for 42 days in vivo. Supplementation of murine RAW264.7 macrophages in culture with increasing concentrations of quercetin (1, 10, 20 μmol/L) resulted in a significant increase in PON2 mRNA and protein levels, as compared to untreated controls. Unlike quercetin, its glucuronidated metabolite quercetin-3-glucuronide did not affect PON2 gene expression in cultured macrophages. However the methylated quercetin derivative isorhamnetin enhanced PON2 gene expression in RAW264.7 cells to similar extent like quercetin. Although supplementing human volunteers with quercetin was accompanied by a significant increase in plasma quercetin concentration, dietary quercetin supplementation did not change PON2 mRNA levels in human monocytes in vivo. Current data indicate that quercetin supplementation increases PON2 levels in cultured monocytes in vitro but not in human volunteers in vivo.
- 23 September 2009
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 10 (9) , 4168-4177
Open AccessEffect of Quercetin on Paraoxonase 2 Levels in RAW264.7 Macrophages and in Human Monocytes—Role of Quercetin Metabolism
There is increasing evidence that the intracellular antioxidant enzyme paraoxonase 2 (PON2) may have a protective function in the prevention of atherogenesis. An enhancement of PON2 activity by dietary factors including flavonoids is therefore of interest. In the present study we determined the effect of quercetin on paraoxonase 2 levels in cultured murine macrophages in vitro and in overweight subjects with a high cardiovascular risk phenotype supplemented with 150 mg quercetin/day for 42 days in vivo. Supplementation of murine RAW264.7 macrophages in culture with increasing concentrations of quercetin (1, 10, 20 μmol/L) resulted in a significant increase in PON2 mRNA and protein levels, as compared to untreated controls. Unlike quercetin, its glucuronidated metabolite quercetin-3-glucuronide did not affect PON2 gene expression in cultured macrophages. However the methylated quercetin derivative isorhamnetin enhanced PON2 gene expression in RAW264.7 cells to similar extent like quercetin. Although supplementing human volunteers with quercetin was accompanied by a significant increase in plasma quercetin concentration, dietary quercetin supplementation did not change PON2 mRNA levels in human monocytes in vivo. Current data indicate that quercetin supplementation increases PON2 levels in cultured monocytes in vitro but not in human volunteers in vivo.
- Open Access
- 1 May 2009
- Published by Elsevier in The Journal of Nutrition
- Vol. 139 (5) , 861-868
Dietary α-Linolenic Acid, EPA, and DHA Have Differential Effects on LDL Fatty Acid Composition but Similar Effects on Serum Lipid Profiles in Normolipidemic Humans
Our aim was to study the effects of increased dietary intake of α-linolenic acid (ALA), eicosapentaenoic acid (EPA), or docosahexaenoic acid (DHA) on
- 1 May 2009
- Published by Elsevier in The Journal of Nutrition
- Vol. 139 (5) , 861-868
Open AccessDietary α-Linolenic Acid, EPA, and DHA Have Differential Effects on LDL Fatty Acid Composition but Similar Effects on Serum Lipid Profiles in Normolipidemic Humans
Our aim was to study the effects of increased dietary intake of α-linolenic acid (ALA), eicosapentaenoic acid (EPA), or docosahexaenoic acid (DHA) on
- 14 November 2008
- Published by S. Karger AG in Annals of Nutrition and Metabolism
- Vol. 53 (3-4) , 182-187
Effects of Dietary α-Linolenic Acid, Eicosapentaenoic Acid or Docosahexaenoic Acid on Parameters of Glucose Metabolism in Healthy Volunteers
Aim: To investigate the effects of α-linolenic acid (ALA) and purified eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) on fasting concentrations of glucose, insulin, fructosamine, on glycosylated haemoglobin (HbA1c) and on insulin sensitivity. Methods: A randomized strictly controlled dietary study in 48 healthy volunteers (13 males, 35 females) of normal body weight (mean age 25.9 years) with three dietary groups (ALA, EPA and DHA) and a parallel design, consisting of two consecutive periods. Subjects received a 2-week wash-in diet rich in monounsaturated fatty acids followed by experimental diets enriched with equal amounts of ALA, EPA, or DHA for 3 weeks. Mean dietary intake of ALA in the ALA group was 6.0 g/day (2.5% of energy intake), mean intake of EPA in the EPA group was 2.8 g/day (1.1% of energy intake) and mean intake of DHA in the DHA group was 2.9 g/day (1.1% of energy intake). Results: Fasting serum concentrations of insulin and fructosamine and of HbA1c did not change significantly after consuming the ALA, EPA or DHA diet. Fasting serum glucose levels did not change significantly following either the ALA or DHA diet. During the EPA diet, fasting glucose concentration slightly increased by 0.15 mmol/l (p < 0.05). All measured values of all subjects were in the reference ranges for healthy adults. No effects on insulin sensitivity indicated by the HOMA insulin resistance index could be observed. Conclusions: Except for the minor effect of EPA on fasting glucose levels, the moderate amounts of dietary ALA, EPA or DHA administered in this study did not significantly affect blood concentrations of glucose, insulin, fructosamine and HbA1c in healthy normal-weight men and women over a time course of 3 weeks.
- 14 November 2008
- Published by S. Karger AG in Annals of Nutrition and Metabolism
- Vol. 53 (3-4) , 182-187
Effects of Dietary α-Linolenic Acid, Eicosapentaenoic Acid or Docosahexaenoic Acid on Parameters of Glucose Metabolism in Healthy Volunteers
Aim: To investigate the effects of α-linolenic acid (ALA) and purified eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) on fasting concentrations of glucose, insulin, fructosamine, on glycosylated haemoglobin (HbA1c) and on insulin sensitivity. Methods: A randomized strictly controlled dietary study in 48 healthy volunteers (13 males, 35 females) of normal body weight (mean age 25.9 years) with three dietary groups (ALA, EPA and DHA) and a parallel design, consisting of two consecutive periods. Subjects received a 2-week wash-in diet rich in monounsaturated fatty acids followed by experimental diets enriched with equal amounts of ALA, EPA, or DHA for 3 weeks. Mean dietary intake of ALA in the ALA group was 6.0 g/day (2.5% of energy intake), mean intake of EPA in the EPA group was 2.8 g/day (1.1% of energy intake) and mean intake of DHA in the DHA group was 2.9 g/day (1.1% of energy intake). Results: Fasting serum concentrations of insulin and fructosamine and of HbA1c did not change significantly after consuming the ALA, EPA or DHA diet. Fasting serum glucose levels did not change significantly following either the ALA or DHA diet. During the EPA diet, fasting glucose concentration slightly increased by 0.15 mmol/l (p < 0.05). All measured values of all subjects were in the reference ranges for healthy adults. No effects on insulin sensitivity indicated by the HOMA insulin resistance index could be observed. Conclusions: Except for the minor effect of EPA on fasting glucose levels, the moderate amounts of dietary ALA, EPA or DHA administered in this study did not significantly affect blood concentrations of glucose, insulin, fructosamine and HbA1c in healthy normal-weight men and women over a time course of 3 weeks.